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Abstract
Myofibroblasts, and the extracellular matrix (ECM) in which they reside, are critical components of wound
healing and fibrosis. The ECM, traditionally viewed as the structural elements within which cells reside, is
actually a functional tissue whose components possess not only scaffolding characteristics, but also growth factor,
mitogenic, and other bioactive properties. Although it has been suggested that tissue fibrosis simply reflects an
‘exuberant’ wound-healing response, examination of the ECM and the roles of myofibroblasts during fibrogenesis
instead suggest that the organism may be attempting to recapitulate developmental programmes designed to
regenerate functional tissue. Evidence of this is provided by the temporospatial re-emergence of embryonic ECM
proteins by fibroblasts and myofibroblasts that induce cellular programmatic responses intended to produce a
functional tissue. In the setting of wound healing (or physiological fibrosis), this occurs in a highly regulated
and exquisitely choreographed fashion which results in cessation of haemorrhage, restoration of barrier integrity,
and re-establishment of tissue function. However, pathological tissue fibrosis, which oftentimes causes organ
dysfunction and significant morbidity or mortality, likely results from dysregulation of normal wound-healing
processes or abnormalities of the process itself. This review will focus on the myofibroblast ECM and its role
in both physiological and pathological fibrosis, and will discuss the potential for therapeutically targeting ECM
proteins for treatment of fibrotic disorders.
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Introduction
Myofibroblast activation is a key event in physiolog-
ical and pathological tissue repair. Myofibroblasts are
the primary extracellular matrix (ECM)-secreting cells
during wound healing and fibrosis, and are largely
responsible for the contractility of scar tissue as it
matures [1,2]. The contribution of myofibroblasts and
their elaborated ECM to normal and pathological
tissue repair [3] has been well studied in the lung
[4–6], liver [7–9], kidney [10,11], skeletal muscle
[12], systemic sclerosis [13–15], heart [16–18], and
the stromal reaction to tumours [19,20].
A number of recent reviews have considered the
nature of myofibroblast progenitors in different organs
[21], including resident fibroblasts [3,19,22–25], fibro-
cytes [26–28], smooth muscle cells [29], pericytes
[30–33], epithelial and endothelial cells undergoing
endothelial (EndoMT) or epithelial-to-mesenchymal
transition (EMT) [34–38], mesenchymal stromal
cells [39,40], and hepatic stellate cells [23], to name
only the most prominent. Others have focused on
the chemical and mechanical conditions controlling
myofibroblast formation and survival [41], functional
and phenotypic characteristics [42,43], and their
suitability as therapeutic targets [44–48]. Due to space
constraints, these concepts will not be explored here.
Despite the abundant literature concerning the
myofibroblast, surprisingly little focuses on specific
features and functions of the myofibroblast ECM.
Indeed, disturbance of the ECM and remodelling by
myofibroblasts has a profound impact on their own
behaviour and that of other cell types sharing the
same microenvironment. This is intuitive since the
ECM performs a multitude of biological functions,
including providing mechanical stability, protection,
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and guidance for cells [49–51], and acting as a
repository for growth factors [52–54].
The myofibroblast: born to produce and
remodel ECM
Myofibroblasts were first identified four decades ago as
fibroblastic cells that simultaneously exhibit prominent
endoplasmic reticulum and contractile microfilament
bundles in wound granulation tissue [55]. One promi-
nent feature of the myofibroblast is the neo-expression
of α-smooth muscle actin (α-SMA) in stress fibres [56],
the molecular basis for their high contractile activity.
However, not all α-SMA-expressing cells are myofi-
broblasts. For example, α-SMA-positive cells that do
not form microfilament bundles are not considered
myofibroblasts since they are lacking their defining
contractile element [57]. Conversely, α-SMA-negative
fibroblasts that express microfilament bundles are func-
tional contractile myofibroblasts, at least in vivo. Since
fibroblasts almost inevitably form microfilament bun-
dles (stress fibres) in standard cell culture conditions,
‘myofibroblast’ denotes α-SMA-positive stress fibre-
forming cells.
It bears mentioning that much of our understanding
of myofibroblast behaviour arises from in vitro studies
in which culture conditions vary greatly (eg cultur-
ing in ECM-coated dishes, culturing on ‘soft’ agar,
culturing in attached or detached collagen gels). This
may account for discrepant results among studies and
should be considered when interpreting data reported
in the literature. One must also recognize that in vivo,
fibroblasts and myofibroblasts encounter multiple ECM
components simultaneously, thereby potentially alter-
ing behaviours from those observed in the experimen-
tal setting. Certainly, differences between fibroblast
behaviour in two-dimensional and three-dimensional
culture conditions are well documented [58] and also
inject variability into the results of in vitro studies.
Finally, the role of mechanotransduction – the sens-
ing of matrix stiffness and response to such stiffness
by cells – is beginning to be elucidated in fibroblasts
and myofibroblasts, and also adds yet another layer
of complexity to our understanding of the myofibrob-
last ECM. Indeed, a percentage of fibroblasts sponta-
neously acquire a myofibroblast phenotype in culture
[57,59], likely due to stiffness of the culture vessel.
Although collagen I and collagen III are often cited
as the primary ECM proteins expressed by myofibrob-
lasts, the myofibroblast produces myriad other ECM
proteins during wound repair and fibrosis, such as col-
lagen types IV, V, and VI [60]; glycoproteins; and pro-
teoglycans such as fibronectin, laminin, and tenascin
[3,61–72]. It is worth noting, however, that myofibrob-
lasts are not necessarily the only source of these pro-
teins, as epithelial, inflammatory, and endothelial cells
may all produce these proteins as well. A schematic
of the myofibroblast ECM to be discussed is shown in
Figure 1.
Collagens
Collagens are primarily structural proteins composed of
three procollagen chains configured in a classic triple
helical pattern. Early in the course of wound granu-
lation, myofibroblasts deposit type III collagen. This
form imparts a measure of plasticity to the wound in
the early phase of healing, although recent data suggest
that collagen III deficiency promotes myofibroblast dif-
ferentiation and wound contraction [73]. When granu-
lation tissue is resorbed following physiological wound
repair, myofibroblasts undergo apoptosis (see below)
and the more rigid type I collagen is biochemically
identified. Under pathological conditions (eg the pro-
liferative cellular phase of palmar fibromatosis or areas
of mesenchymal stromal invasion in breast carcino-
mas), type III collagens appear to be increased [74,75],
as are type V collagens in desmoplastic human breast
carcinomas and in small airway fibrosis of bronchi-
olitis obliterans complicating chronic lung transplant
rejection [76–78]. Of course, densely fibrotic tissues
demonstrate an abundance of type I collagens, but also
type VI collagens [79–83].
As wound healing approaches completion, apoptotic
gene programmes are expressed within myofibroblasts,
resulting in a relatively hypocellular scar. Cytokines
that stimulate ECM synthesis early on are repressed
once wound closure is completed and a functional base-
ment membrane has been synthesized, thus suggesting
the existence of a feedback loop [84]. However, in
pathological fibrosis, evidence suggests that failure to
initiate apoptosis of myofibroblasts (or decreased sen-
sitivity to apoptotic stimuli) accounts for the seeming
persistence of these cells in fibrotic tissues.
Fibronectins (FNs)
FN is expressed by multiple cell types and plays a
key role in cell adhesive and migratory behaviour
[85,86]. The functional FN dimer consists of two sim-
ilar or identical subunits of 220–250 kDa that are held
together by two disulphide bonds near their carboxyl-
termini. Like many glycoproteins, each monomer
consists of a combination of different types of homol-
ogous repeating domains; in the case of FN, there are
three, termed types I, II, and III. However, by virtue
of alternative splicing of the pre-mRNA, two extra
type III repeats (termed EDA for extra domain A and
EDB for extra domain B) may be inserted into the
mature protein; the splicing of these domains is inde-
pendent of each other [85,87] but is highly up-regulated
by the pro-fibrotic cytokine TGF-β [88]. Alternative
splicing of FN is particularly prominent during embry-
onic development, as well as during wound heal-
ing, pathological fibrosis, and malignancy, and gives
rise to the term ‘oncofetal’ ECM. Evidence suggests
that alternatively-spliced EDA FN (but not plasma
FN) is necessary for TGF-β1-induced myofibroblast
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Figure 1. The myofibroblast matrix. Schematic of some of the ECM molecules relevant to tissue fibrosis. The myofibroblast (centre, with
red stress fibres containing α-smooth muscle actin) lies enmeshed in its ECM (green). Components of the ECM are depicted (clockwise,
from the 12 o’clock position): elastins, fibrillins and LTBPs, proteoglycans, tenascins, matricellular proteins, collagens, and fibronectins. The
myofibroblast encounters, signals, and modulates the expression of these various components as outlined in the text.
differentiation [89,90] and is thus a critical component
of the myofibroblast ECM.
As a separate contribution, FN also binds a large
number of growth factors that may promote myofi-
broblast differentiation. Most notably, FN localizes
latent TGF-β1 complex by binding latent TGF-β
binding proteins (LTBPs, see below) [91]. In addition,
FN binds vascular endothelial growth factor (VEGF)
[92], bone morphogenetic protein (BMP) 1 [93], hep-
atocyte growth factor (HGF) [94], fibroblast growth
factor (FGF)-2 [95], and platelet-derived growth factor
(PDGF) [96], all of which may contribute to the
myofibroblast phenotype.
Elastin
Elastin, a major ECM protein involved in connective
tissue homeostasis, provides organs with structural
integrity and is responsible for absorption of mechan-
ical overload preventing damage [97]. Smooth muscle
cells and fibroblasts are the major elastin-producing
cells in normal tissues [98] such as skin, heart, arteries,
and lung, which all undergo cyclic mechanical loading
and unloading throughout life. Elastin deposition and
organization occurs mainly during the late fetal and
early neonatal periods and is reduced during maturity
to a low turnover rate [99].
It has been generally understood that elastin produc-
tion by fibroblasts is low or absent following injury,
which partly accounts for the reduced elasticity and
breaking strength of scar tissue compared with the
intact connective tissue [52]. Because of the low elastin
turnover in normal and injured skin and arteries, current
strategies aim to supply elastin-like proteins either by
grafting [100–102] or by stimulating cellular elastin
production [103,104]. However, some studies have
shown that elastin production by fibroblasts is quite
elevated after tissue damage in response to a num-
ber of cytokines, such as TNF-α, IL-1β, and TGF-β1
[105,106]. For example, in constrictive bronchiolitis
obliterans, characterized by fibrosis development in the
small airways, α-SMA-positive myofibroblasts demon-
strated enhanced elastin expression [107].
Fibrillins and LTBPs
In addition to the major fibrillar components, the myofi-
broblast ECM contains a microfibrillar network formed
by members of the fibrillin and latent TGF-β binding
protein (LTBP) family. In humans, these glycoprotein
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families consist of three homologous fibrillin isoforms
(fibrillin-1, -2, and -3) and four LTBPs (LTBP-1, -2, -3,
and -4) that are mainly characterized by highly repeti-
tive and disulphide-rich domains. Microfibrils provide
the basis for tropoelastin binding during elastic fibre
formation, enhance the structural integrity of tissues
and organs, and target growth factors such as TGF-β
and bone morphogenic protein (BMP) to the ECM
[108–110]. The disruption of microfibrillar assembly
or growth factor association with fibrillins due to muta-
tions within fibrillin genes leads to clinical relevant
pathological connective tissue conditions such as Mar-
fan’s syndrome, congenital contractual arachnodactyly,
and systemic scleroderma [111–115].
LTBPs share similarities with fibrillins in their repet-
itive sequence and domain structure. However, LTBPs
are considerably smaller, ranging from 125 to 160 kDa
when compared with fibrillins (∼350 kDa). Analysis
of LTBP isoforms from cultured human hepatic myofi-
broblast ECM reveals all four isotypes, suggesting that
these proteins may play a role in liver fibrosis [116].
Moreover, culture studies may give an insight into the
sequence of events in ECM assembly by fibroblasts
during embryogenesis and tissue repair. Recent mouse
fibrillin-1 knock-out studies showed that LTBP-1
incorporation into the ECM of fibroblasts depends on
a FN network compared with the ECM association
of LTBP-3 and LTBP-4, which depends on fibrillin-1
microfibrils [117]. In fibroblasts that are missing the
gene for FN, LTBP-1 fails to incorporate into the
ECM in the early phase but can be assembled in later
stages [118].
LTBP-1 is crucial for tissue repair, fibrosis, and
myofibroblast biology because it serves as a stor-
age protein for TGF-β1. The TGF-β family comprises
multipotent cytokines modulating cell growth, apopto-
sis, inflammation, and ECM synthesis. In mammals,
these functions are mediated by the widely expressed
three isoforms TGF-β1, TGF-β2, and TGF-β3 that are
encoded by three different genes of high homology
[119]. TGF-β1 appears to be the most prevalent iso-
form that associates with fibroblast-to-myofibroblast
activation [120], although both of the other isoforms
have also been demonstrated to perform this action
in vitro [121]. In vivo, TGF-β3 appears to attain a
myofibroblast-supressing role [121,122]. LTBP-1 reg-
ulates the bioactivity of TGF-β1 at multiple levels:
(1) it promotes efficient latent TGF-β1 secretion by
assembling the large latent complex [123]; (2) it tar-
gets latent TGF-β1 as a large latent complex to the
ECM by interacting with different proteins including
FN and fibrillin [109,124,125]; and (3) it controls and
directs cell-mediated TGF-β1 activation [125–127].
In addition to the aforementioned, myriad other
ECM components can be found in the myofibroblast
ECM, including fibulins, matricellular proteins (such
as CCN proteins, osteopontin, periostin, and SPARC,
to name but a few), tenascins, and thrombospondins.
These proteins have all been implicated in fibrogenesis
and wound repair to various degrees, with the matricel-
lular protein CCN2 (connective tissue growth factor,
CTGF) and tenascin-C perhaps being the best studied.
Similarly, experimental data supporting the role of
WISP-1, SPARC, osteopontin, and thrombospondins in
myofibroblast functions in wound healing and fibrosis
have been amply documented [52,128–143]. Below,
we will highlight some recent evidence of the roles of
these ECM proteins in wound repair and fibrosis.
CCN2 (CTGF)
CCN proteins [so named because of the names of
the first three family members identified: cysteine-rich
61 (CYR61), connective tissue growth factor (CTGF),
and nephroblastoma overexpressed (NOV) [144]] are
integral components of the ECM related to fibrosis and
myofibroblast activation. Despite the designation as a
growth factor, CCN2 is not a cytokine but an integral
ECM protein that exerts its function through binding
of cell integrins alone or recruitment of co-receptors
[145]. A number of reviews have summarized CCN2
functions in fibrosis [146–148].
Expression of CCN2 (CTGF) is locally up-regulated
in a variety of fibrotic conditions and elevated in the
serum of subjects with fibrosis. In addition, muta-
tions in the CCN2 gene promoter are associated
with systemic sclerosis in humans [149]. Experimen-
tally, blocking or deleting CCN2 efficiently reduces
fibrosis, thus identifying CCN2 as a potential criti-
cal modulator of fibrosis. However, subsequent studies
seem to suggest that activating functions of CCN2
occur either up- or down-stream of TGF-β1 signalling
since simultaneous blocking of TGF-β1 abolished
their myofibroblast-activating effect [3,148]. TGF-β1
induces CCN2 expression in a variety of fibroblast cul-
ture and animal fibrosis models, nourishing the concept
that CCN2 is a mere downstream mediator of TGF-β1
in myofibroblast differentiation [131]. However, differ-
ent fibroblast culture models demonstrated expression
of CCN2 in response to factors other than TGF-β1,
such as endothelin-1 [150]. In many organs, however,
CCN2 seems to work synergistically with TGF-β1 in
enhancing fibrosis but does not induce fibrosis and/or
myofibroblast activation in the absence of TGF-β1 or
injury [151,152].
Tenascin-C
Tenascin-C is a member of the tenascin family of ECM
proteins (which also include tenascins-X, -R, and -W).
Tenascin-C is classically regarded as a marker for the
immature ECM in the earlier phases of tissue repair,
promoting stromal cell population of provisional ECM
by generating a migration-supporting adhesive environ-
ment and exerting chemokinetic effects [153]. Indeed,
tenascin-C plays a role in myofibroblast recruitment
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[154]. Whereas tenascin-C is down-regulated in nor-
mally healing wounds, it persists in hypertrophic scar
tissue, where it seems to prevent cell apoptosis and
prolongs the ECM synthesis and proliferative phase
[153,155]. Tenascin-C null mice are protected against
fibrosis in the lung [156] and liver [157] with reduced
amounts of α-SMA-positive myofibroblasts. Less is
known about the possible implication of other tenascin
family members in myofibroblast biology and fibrosis.
Tenascin-X knock-out mice exhibit reduced collagen
amounts in skin dermis, which shares phenotypic
similarities with the human Ehlers–Danlos syndrome,
including increased extensibility and reduced strength
of the skin [158,159]. Although cutaneous wounds
of tenascin-X knock-out mice have reduced breaking
strength, the contribution of myofibroblasts to the
impaired biomechanical properties of the granulation
tissue has not been tested yet [160].
Proteoglycans
Proteoglycans (including heparan sulphate proteogly-
cans, hyaluronan, syndecans, and small leucine-rich
proteoglycans) are critical components of the wound-
healing response and are also implicated in tissue fibro-
sis. Experimental and mechanistic studies implicate
these molecules in facilitating the assembly of matri-
ces and the incorporation of growth factors (such as
LTBP-1/TGF-β complexes) into the ECM [161].
Hyaluronan has long been associated with condi-
tions of fibrosis, and hyaluronic acid (HA) is clinically
used as a serum biomarker for liver fibrosis [162]. In
addition, HA is purported to regulate myofibroblast
activation and persistence in a TGF-β1-dependent man-
ner [163,164]. The mechanisms of this action are not
entirely clear, although fibroblast binding to HA posi-
tions the TGF-β1 receptor close to the HA receptor
CD44, which affects downstream TGF-β1 signalling
[165]. HA also stabilizes cell–ECM adhesions [166],
which are crucial for myofibroblast mechanosensing
and activation [167]. Fibroblasts deficient of the HA
receptor CD44 displayed impaired migration, stress
fibre formation, and production of active TGF-β1, pro-
cesses that are all dependent on cell adhesion [168].
Consistently, conditional overexpression of HA syn-
thase 2 in α-SMA-positive lung myofibroblasts pro-
duced an invasive phenotype that promoted fibrosis
progression in bleomycin-treated mouse lungs [169].
The same study showed that conditional deletion of
HA synthase 2 under control of the Col1α2 promoter or
inhibition of CD44 inhibited the aggressive myofibrob-
last phenotype and reduced development of fibrosis.
Supported by these findings, HA signalling emerges as
a novel target for therapeutic anti-fibrotic interventions.
Syndecans are another class of heparan sulphate
proteoglycans that have been shown to affect organ
fibrosis [170–172]. Shedding of syndecan-1 (CD138)
by matrix metalloproteinases (MMPs) and oxidative
stress was shown to contribute to fibrosis development
[173,174] and syndecan-1 supports FN fibrillogenesis
[175]. The direct effects of syndecans or syndecan
fragments on myofibroblast activation have not yet
been tested. However, syndecan-2 is known to mod-
ulate TGF-β signalling and TGF-β receptor expression
presumably by directly binding to TGF-β1 [176]. Fur-
thermore, syndecan-4 knock-out mice exhibit reduced
myofibroblast activation after myocardial infarct [177]
and in an animal model of lung fibrosis [178].
Small leucine-rich proteoglycans (SLRPs) comprise
a group of proteoglycans with a small protein core
and unique tandem leucine-rich repeats. Among the
best studied SLRPs are decorin, biglycan, lumican, and
fibromodulin [179]. SLRPs fulfil a variety of functions
that have a direct impact on ECM and cell home-
ostasis in fibrocontractive diseases; they regulate cell
survival and collagen organization and they bind to
growth factors, in particular TGF-β1 [180,181]. SLRPs
are often up-regulated in different fibrotic conditions
[179], which contradicts the general observation that
they act as negative regulators of myofibroblast activa-
tion. By contrast, SLRPs are down-regulated in dermal
scarring, correlating with fibrotic contractures [182].
This discrepancy may be explained by SLRP perform-
ing different functions in different phases of ECM
remodelling during repair and fibrosis. For example,
decorin potentially regulates myofibroblast activation
by virtue of binding to active TGF-β1 [183]. Simi-
larly, biglycan has anti-fibrogenic properties similar to
decorin. Biglycan-deficient cultured cardiac fibroblasts
showed enhanced myofibroblast activation and contrac-
tile function due to increased TGF-β1 signalling [184].
Much less is known about the role of lumican in fibro-
contractive diseases and regulating the myofibroblast
phenotype, although it is up-regulated during myofi-
broblast activation of corneal fibroblasts [185].
Post-translational modification of the
myofibroblast ECM
In addition to the composition of the ECM, mechanobi-
ological properties also strongly dictate myofibroblast
activation and function. Being contractile cells, myofi-
broblasts sense and modulate stiffness within the ECM
through focal adhesions via integrin binding. More-
over, recent data suggest that mechanical stiffness
alone, independent of TGF-β signalling, can induce
myofibroblast activation in the setting of fibrosis [186].
Thus, stiffness of the ECM is also a critical modulator
of wound healing and fibrosis. Cross-linking of ECM
proteins is the major determinant of tissue stiffening.
Despite the low turnover rate of collagens in struc-
tural tissues such as skin and cartilage, cross-linking of
ECM proteins (particularly collagens) is a potentially
important area of exploitation for therapeutic purposes
in fibrotic disorders. Cross-linking ECM proteins may
result in conformational changes that render epitopes
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‘hidden’ from protease activity, thereby preventing
digestion and remodelling of the ECM. Thus, target-
ing enzymes and other proteins (discussed below) may
provide a means by which fibrotic processes may be
effectively halted or perhaps even reversed.
Transglutaminases (TGs) belong to a large family of
proteins encoded by structural and functionally related
genes [187,188]. The major function of TGs is to
catalyse the Ca2+-dependent formation of inter-protein
isopeptide bridges between γ-carboxyamide glutamine
residues and ε-amino groups in the protein-bound
lysine residues [189,190]. TG2 is the most widely and
ubiquitously expressed TG family member [191,192].
The ECM substrate spectrum of TG2 is large and com-
prises FN, vitronectin, collagen types I/II/V/VII/XI,
laminin, fibrillin, and LTBP-1, to name only the most
prominent [190,193]. Extensive cross-linking of colla-
gen by TG2 produces collagen fibres that are resistant
to degradation and that support myofibroblast-mediated
fibrosis [194]. In addition to the mechanical conse-
quences of TG cross-linked ECM, the interaction of
TG with fibrillins and LTBP-1 modulates the deposition
and activation of TGF-β1. Moreover, TGs are directly
involved in the proteolytic activation of TGF-β1 from
the large latent complex [129], thereby potentially
inducing myofibroblast differentiation.
Other important enzymes that promote ECM protein
cross-linking in normal and pathological tissue repair
belong to the lysyl oxidase (LOX) and lysyl oxidase-
like (LOXL) families. LOX is a copper-dependent
amine oxidase that forms reactive aldehyde groups
from peptidyl lysines in its substrates by oxidative
deamidation; these reactive groups spontaneously form
covalent cross-links [195,196]. The covalent cross-
linking of fibrillar collagen by LOX is of particu-
lar importance in fibrotic disease progression [197].
LOX is up-regulated in conditions of tissue repair and
fibrosis [198] and induced by TGF-β1 in fibroblast
cultures [199–201]. Furthermore, LOX plays a key
role in promoting fibroblast-to myofibroblast activa-
tion in skin, heart, liver, kidney, and lung fibrosis
[195,202–204]. The conversion of fibroblast-secreted
collagen into insoluble fibres by LOX contributes to
the accumulation of stiff ECM and thereby contributes
to the progression/persistence of fibrosis [198,205,206].
In addition to LOX, LOXL2 has been recently iden-
tified to form fibrosis-specific and stable collagen
cross-links [207]. LOXL2 oxidatively deaminates the
ε-amine group of specific lysine residues of collagen
and elastin [208].
Collagen cross-linking also occurs without enzy-
matic support by glycation; although this process is
comparably slow, it is physiologically relevant given
the low turnover time of collagen, with a half-life of
15 years in skin and one order of magnitude longer
in cartilage [209,210]. A variety of fibrotic and pre-
fibrotic conditions such as diabetes are characterized
by pathological levels of advanced glycation end-
products (AGEs) and tissue stiffening due to glycation
[211]. AGEs are pro-fibrotic in that they promote the
production of type I and type III collagens [212,213],
increase fibroblast proliferation [214], induce TGF-β1-
dependent and -independent fibrotic changes [215,216],
and induce collagen glycation [217].
Outlook/conclusions
Given the clear role of ECM as a mediator of fibro-
sis, it seems plausible that these proteins and their
modifiers could be possible anti-fibrotic therapeutic
targets. However, the ubiquitous nature and clear clin-
ical importance of the ECM dictates that efforts be
directed at identifying differences in ECM composi-
tion between normal and disease states. As an example,
using mass spectrometry, our group has evaluated dif-
ferences in ECM composition between normal and
fibrotic human lung, identifying a number of ECM
molecules clearly overexpressed in the diseased organ
[218]. Although further study is needed to determine
whether these changes reflect pathogenic mechanisms
or are merely epiphenomena, we believe that ECM
molecules, domains, or cross-links may offer possible
novel therapeutic targets for patients with progressive
fibrotic disorders.
Among the list of major myofibroblast ECM com-
ponents, FN seems to be an appropriate target to con-
trol myofibroblast development and survival. However,
the critical nature of FN to development indicates a
need for specific targeting within the molecule. In this
regard, the EDA domain of FN is more attractive as a
potential therapeutic target for the treatment of fibrotic
diseases because it is a specific and crucial component
of the myofibroblast ECM that is highly up-regulated in
a variety of fibrotic diseases but virtually absent from
most normal connective tissues [219–221].
In addition to targeting EDA FN, a second poten-
tial target currently under investigation is LOXL2
[222,223]. Initial studies targeting LOX using the
inhibitor β-aminopropionitrile (BAPN) reduced colla-
gen cross-linking and scarring but did not proceed to
clinical trials due to drug toxicity [224]. However,
LOXL2 has also been identified in, and is associated
with, fibrotic tissues [208,225]. LOXL2 antibodies are
currently being considered for clinical trials in fibrotic
disorders [222,223].
Besides interfering with ECM proteins, targeting
integrins as specific ECM receptors emerges as another
promising therapeutic approach [226]. Many integrins
contribute to fibrosis and myofibroblast differentia-
tion through various pathways, including α3β1 [227],
α11β1 [228,229], integrin αvβ3 [230], α4β7 [90], and
β1 integrin [186,231]. Of particular interest, αvβ6 inte-
grins, necessary for epithelial activation of TGF-β1
[232], and αvβ5 integrins, involved in mesenchymal
cell activation of TGF-β1, have emerged as potential
targets in fibrotic disorders. Currently, antibody ther-
apy to αvβ6 integrins is being tested in a phase 2 trial
of patients with idiopathic pulmonary fibrosis (Clini-
caltrials.gov identifier NCT01371305).
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In summary, experimental data suggest that both the
myofibroblast and its ECM are critical contributors to
pathological fibrogenesis in a variety of organs. Our
knowledge in this arena has provided the foundation
for upcoming and current clinical trials in patients
with fibrotic disorders. Further investigation into the
mechanisms by which the ECM promotes fibrosis will
likely identify other promising potential targets for
therapeutic intervention.
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